BADBIR中符合与不符合临床试验入组标准的银屑病患者在药物停用、疗效及安全性方面的比较
该观察性研究纳入英国和爱尔兰157家皮肤科中心的BADBIR登记患者,比较符合与不符合生物制剂临床试验入组标准的银屑病患者在药物停用、疗效及严重不良事件上的差异。不符合标准者(依那西普367例、阿达木单抗282例、乌司奴单抗394例)在6和12个月时PASI绝对改善较小(阿达木单抗、乌司奴单抗),且严重不良事件发生率显著更高(依那西普IRR 1.9,95%CI 1.4-2.6;阿达木单抗IRR 2.0,95%CI 1.5-2.6;乌司奴单抗IRR 2.8,95%CI 2.1-3.8),药物停用无显著差异。
要点
- 不符合临床试验标准的患者严重不良事件风险更高:依那西普IRR 1.9,阿达木单抗IRR 2.0,乌司奴单抗IRR 2.8。
- 不符合标准者在6和12个月时PASI绝对改善较小(阿达木单抗、乌司奴单抗)。
- 符合与不符合标准者之间药物停用无显著差异。
核心结论
- 临床试验的疗效和安全性结果不能代表BADBIR中不符合此类试验标准的真实世界患者。
研究设计与样本
- 观察性研究,使用英国和爱尔兰157家皮肤科中心,将生物制剂治疗银屑病临床试验的入组标准应用于BADBIR登记中接受标准临床护理的生物制剂患者。
- 纳入BADBIR中注册使用依那西普(仅Enbrel;n=1509)、阿达木单抗(n=4000)和乌司奴单抗(n=1627)且至少1次随访的银屑病患者。
- 入组标准提取自依那西普、阿达木单抗和乌司奴单抗治疗中重度银屑病的3期注册试验。
- BADBIR中基线PASI缺失或基线PASI值低于10(依那西普)或低于12(阿达木单抗;乌司奴单抗)但其他方面符合条件者被单独分析。
- 入组类别包括:符合、不符合、仅基线PASI不足、仅基线PASI缺失。
主要发现
- 7136例患者的平均(SD)年龄为45(13)岁,其中女性2924例(41%),男性4212例(59%)。
- 7136例中,依那西普839例(56%)、阿达木单抗2219例(56%)、乌司奴单抗754例(46%)的注册被归类为符合。
- 不符合的最常见原因:依那西普为糖尿病143例(9%),乌司奴单抗为糖尿病201例(12%),阿达木单抗为非慢性斑块状银屑病157例(4%)。
- 被归类为不符合的患者(依那西普367例[24%];阿达木单抗282例[7%];乌司奴单抗394例[24%])在6和12个月后PASI绝对变化较小(阿达木单抗、乌司奴单抗)。
- 与符合类别相比,不符合类别严重不良事件发生率显著更高:依那西普IRR 1.9(95%CI 1.4-2.6);阿达木单抗IRR 2.0(95%CI 1.5-2.6);乌司奴单抗IRR 2.8(95%CI 2.1-3.8)。
关键数值与推荐
- 主要结局:12个月时按停药原因和入组类别及药物分层的药物停用累积发生率。
- 主要结局:基线至6和12个月PASI绝对变化的线性回归。
- 主要结局:12个月时各入组类别间按药物计算的严重不良事件发生率比(IRR)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patients with psoriasis enrolled in clinical trials of biologics may not be representative of the real-world population. There is evidence that patients ineligible for such trials have a greater risk of serious adverse events (SAEs), but the effect on drug discontinuation and effectiveness are unknown. OBJECTIVE: To determine whether (1) drug discontinuation, (2) effectiveness, and (3) rates of SAEs differ in patients with psoriasis categorized as eligible or ineligible for clinical trials. DESIGN, SETTING, AND PARTICIPANTS: An observational study using 157 dermatology centers in the United Kingdom and Republic of Ireland was carried out wherein we applied the eligibility criteria of clinical trials of biologic therapies for psoriasis to patients who were being followed up in the British Association of Dermatologists Biologic Interventions Register (BADBIR) and being prescribed biologics as part of standard clinical care. Patients with psoriasis registered to BADBIR who were taking etanercept (enbrel only; n = 1509), adalimumab (n = 4000), and ustekinumab (n = 1627) with at least 1 follow-up visit. Eligibility criteria were extracted from phase 3 licensing trials for etanercept, adalimumab, and ustekinumab for the treatment of moderate to severe psoriasis. Patients in BADBIR with a missing baseline Psoriasis Area and Severity Index (PASI) or baseline PASI value less than 10 (etanercept) or less than 12 (adalimumab; ustekinumab) but who would otherwise be eligible were investigated separately. Eligibility categories applied to BADBIR included: eligible, ineligible, insufficient baseline PASI only, and missing baseline PASI only. MAIN OUTCOMES AND MEASURES: (1) Drug discontinuation: cumulative incidence at 12 months by stop reason per eligibility category and drug; (2) effectiveness: linear regression of absolute change in PASI from baseline to 6 and 12 months; and (3) SAEs: incidence rate ratio (IRR) at 12 months between eligibility categories per drug. RESULTS: The mean (SD) age of the 7136 patients included in the analysis was 45 (13) years and 2924 (41%) were women and 4212 (59%) were men. Of 7136 patients, 839 (56%) etanercept, 2219 (56%) adalimumab, and 754 (46%) ustekinumab registrations were categorized as eligible. The most common reasons for ineligibility were diabetes (etanercept, 143 [9%]; ustekinumab, 201 [12%]) and nonchronic plaque psoriasis (adalimumab, 157 [4%]). Patients categorized as ineligible (etanercept, 367 [24%]; adalimumab, 282 [7%]; ustekinumab, 394 [24%]) achieved a smaller absolute change in PASI after 6 and 12 months (adalimumab, ustekinumab), and had significantly higher rates of SAEs compared with the eligible category (etanercept: IRR, 1.9; 95% CI, 1.4-2.6; adalimumab: IRR, 2.0; 95% CI, 1.5-2.6; ustekinumab: IRR, 2.8; 95% CI, 2.1-3.8). No significant differences in drug discontinuation were observed between categories. CONCLUSIONS AND RELEVANCE: Clinical trial effectiveness and safety outcomes are not representative of real-world patients in BADBIR patients categorized as ineligible for such trials.
引用
- Mason KJ, Barker JNWN, Smith CH, et al. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR. JAMA Dermatol. 2018. PMID: 29590279. doi:10.1001/jamadermatol.2018.0183
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。